Narrative review discusses Treg therapy for non-malignant diseases with noted limitations
This narrative review focuses on the application of Regulatory T cell therapy for non-malignant diseases, specifically autoimmune disorders, transplantation-related complications, and allergic conditions. The scope of the article covers the current understanding of this intervention within these patient populations. The authors synthesize existing arguments regarding the potential benefits of this approach for managing these complex conditions.
The review addresses secondary outcomes related to efficacy and safety. However, the source material did not report specific adverse events, serious adverse events, discontinuations, or tolerability data. Furthermore, the sample size and setting were not reported in the original text. The authors acknowledge significant limitations concerning cell stability, expansion methodologies, and functional heterogeneity.
Due to the nature of a narrative review and the lack of reported primary outcomes or specific trial data, the practice relevance remains uncertain. Clinicians should interpret these findings with caution given the absence of quantitative data and the noted methodological gaps in the underlying evidence.